rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
16
|
pubmed:dateCreated |
2008-8-13
|
pubmed:abstractText |
The p21 cyclin-dependent kinase inhibitor was frequently expressed in human malignant pleural mesothelioma (MPM) tissues as well as cell lines. Recent data indicate that p21 keeps tumor cells alive after DNA damage, favoring a survival advantage. In this study, we assessed the possibility of p21 suppression as a therapeutic target for MPM.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
1078-0432
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
14
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
5099-107
|
pubmed:meshHeading |
pubmed-meshheading:18698027-Animals,
pubmed-meshheading:18698027-Antineoplastic Agents,
pubmed-meshheading:18698027-Apoptosis,
pubmed-meshheading:18698027-Camptothecin,
pubmed-meshheading:18698027-Cell Aging,
pubmed-meshheading:18698027-Cell Cycle,
pubmed-meshheading:18698027-Cell Line, Tumor,
pubmed-meshheading:18698027-Cyclin-Dependent Kinase Inhibitor p21,
pubmed-meshheading:18698027-Doxorubicin,
pubmed-meshheading:18698027-Drug Resistance, Neoplasm,
pubmed-meshheading:18698027-Etoposide,
pubmed-meshheading:18698027-Humans,
pubmed-meshheading:18698027-Immunoblotting,
pubmed-meshheading:18698027-In Situ Nick-End Labeling,
pubmed-meshheading:18698027-Male,
pubmed-meshheading:18698027-Mesothelioma,
pubmed-meshheading:18698027-Mice,
pubmed-meshheading:18698027-Mice, Nude,
pubmed-meshheading:18698027-RNA Interference,
pubmed-meshheading:18698027-Transfection,
pubmed-meshheading:18698027-Xenograft Model Antitumor Assays
|
pubmed:year |
2008
|
pubmed:articleTitle |
Enhanced antitumor therapy by inhibition of p21waf1 in human malignant mesothelioma.
|
pubmed:affiliation |
Department of Molecular Pathology and Innovative Therapies, Marche University, Ancona, Italy.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|